A5010550432- COVID-19 Clinical Research Studies
- Chronic Obstructive Pulmonary Disease (COPD) Research
- Long-Term Effects of COVID-19
- Obstructive Sleep Apnea Research
- Human Health and Disease
- Asthma and respiratory diseases
- Respiratory Support and Mechanisms
- Sepsis Diagnosis and Treatment
- Healthcare Systems and Public Health
- Respiratory and Cough-Related Research
- High Altitude and Hypoxia
- Neuroscience of respiration and sleep
- SARS-CoV-2 and COVID-19 Research
- Neonatal Respiratory Health Research
- Intensive Care Unit Cognitive Disorders
- Biomarkers in Disease Mechanisms
- Pneumonia and Respiratory Infections
- Inhalation and Respiratory Drug Delivery
- Pulmonary Hypertension Research and Treatments
- Cardiovascular Syncope and Autonomic Disorders
- Pediatric health and respiratory diseases
- Clostridium difficile and Clostridium perfringens research
- Diverse Approaches in Healthcare and Education Studies
- COVID-19 diagnosis using AI
- Chemical and Physical Studies
Regional Public Health Care Institution "City Hospital No. 5, Barnaul"
2014-2024
St. Petersburg State Medical Academy "City Hospital No. 26"
2022
Altai State Medical University
2012-2015
City Hospital
2015
Effective treatments for patients with severe COVID-19 are needed.To evaluate the efficacy of canakinumab, an anti-interleukin-1β antibody, in hospitalized COVID-19.This randomized, double-blind, placebo-controlled phase 3 trial was conducted at 39 hospitals Europe and United States. A total 454 pneumonia, hypoxia (not requiring invasive mechanical ventilation [IMV]), systemic hyperinflammation defined by increased blood concentrations C-reactive protein or ferritin were enrolled between...
Once a patient has been diagnosed with severe COVID-19 pneumonia, treatment options have limited effectiveness. Opaganib is an oral under investigation being evaluated for of hospitalized patients pneumonia. A randomized, placebo-controlled, double-blind phase 2/3 trial was conducted in 57 sites worldwide from August 2020 to July 2021. Patients received either opaganib (n = 230; 500 mg twice daily) or matching placebo 233) 14 days. The primary outcome the proportion no longer requiring...
Chronic cough declines quality of life and increases risk complications in patients with chronic obstructive pulmonary disease (COPD). Reducing severity associated negative effects is important therapeutic goal COPD. Rengalin anti- protussive activity based on technologically processed antibodies to bradykinin, histamine morphine.To evaluate efficacy safety treatment COPD.Patients (n=238, mean age 64.3±8.2 years) stable COPD persistent despite maintenance therapy (anticholinergics,...
ABSTRACT Rationale There are few treatment options for severe COVID-19 pneumonia. Opaganib is an oral under investigation. Objective Evaluate opaganib in hospitalized patients with Methods A randomized, placebo-controlled, double-blind phase 2/3 trial was conducted 60 sites worldwide from August 2020 to July 2021. Patients received either (n=230; 500mg twice daily) or matching placebo (n=233) 14 days. Main Outcome Measurements Primary outcome the proportion of no longer requiring...
The aim of this study was early differentiation breathlessness due to pulmonary or cardiac disease. conducted in three stages. Firstly, we examined 359 patients aged 18 90 years with confirmed diagnosis asthma ( n = 134, 37.3 %), COPD (n 114, 31.8 and chronic heart failure (CHF) not related lung disease 111, 30.9 %). There were 154 males (42.9 %) 205 females (57.1 We compared frequencies P.M.Simon's "language dyspnea" descriptors (1990) used by excluded characteristics equally often asthma,...
<b>Objective:</b> the rationalization of differential diagnosis dyspnea for patients with asthma, COPD, CHF non-pulmonary origin in primary care <b>Methods:</b> The study included 359 patients: 205 (57.1%) men and 154 (42.9%) women. A comparative analysis frequency occurrence individual phrases «the glossary» (P.M. Simon et al., 1990) simultaneously conducted using Pearson criterion allowed to obtain a modified vocabulary (MDV). <b>Results:</b> MDV is represented by 7 corresponding 6...
<b>Background:</b> According to our data, severe pneumonia (SP) occurs with sepsis (PS) in 92.9% of patients, them - 26.6% septic shock, 7.1% patients sepsis. <b>Objective:</b> Monitoring endothelin-1 (E-1) changes as an indicator endothelial dysfunction and a marker, determining its prognostic significance SP PS. <b>Methods:</b> We have studied the concentration E-1 blood 68 PS at 1, 3-5 7-10 days hospitalization. Died 10 (14.7%) (comparison group), survived 58 (85.3%) (the main group). The...
Цель исследования - изучить распространенность синдрома обструктивного апноэ во сне (СОАС) и эффективность длительной респираторной поддержки в домашних условиях. Изучались данные 249 пациентов (197 мужчин 52 женщин) с расстройствами сна возрасте от 33 до 74 лет. Распространенность СОАС среди сомнологического центра составила 86,4 %. В результате СРАР-терапии индекс / гипопноэ снизился 55,4 ± 5,9 3,4 0,5 ( р < 0,01). Через 6 мес. артериальное давление стабилизировалось у 68,8 % больных, вес...
This multicenter, double-blind, placebo-controlled clinical trial was conducted to obtain additional data on the efficacy and safety of Anaferon for treatment acute respiratory viral infections (ARVI) during seasonal increase in their incidence (RCT Ministry Health Russia No 356 dated 24.07.2018; ClinicalTrials.gov Identifier: NCT03707912). Patients methods. Between October 2018 March 2019, a total 204 patients aged 18 70 years with ARVI symptoms were included this study within first 24...